Articles

Podcasts

Videos

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

The investigators generated a list of 250 genes that are known to regulate individual reactions within the component pathways of the Alzheimer Disease Aberrant Metabolism (ADAM) network.

Researchers Look for Potential Treatments for Alzheimer Disease

Researchers examine how biomarkers are differentially mapped to MRI measures of cortical thickness. 

Researchers Clarify Alzheimer Disease Biomarkers and MRI Measures

At the 76-week mark, reductions in the amyloid plaque level were 85.06 centiloids with donanemab than with placebo.

Donanemab Shows Promise as a Alzheimer Disease Treatment

Alector’s announcement about the INVOKE-2 study follows a similar update regarding its INFRONT-3 study for frontotemporal dementia.

Alector Moving Forward with AL002 Alzheimer Disease Trial

The Cassava Sciences agent showed 6-month improvements in both ADAS-Cog and NPI scores, and a phase 3 trial is expected to begin in late 2021.

Simufilam Shows Promise Improving Cognition, Behavior in Alzheimer Disease Patients

Fewer patients who received masitinib 4.5 mg/kg/day reached severe dementia stage.

Masitinib Shows Promise in Alzheimer Disease Study

Researchers from USC propose a direct neurotoxic effect of particulate matter smaller than 2.5 μm.

Particulate Matter Increases Future Risk of Alzheimer Disease

After a sudden reversal and complex analyses, aducanumab’s future rests in the hands of the FDA while the community stands split on if the available data are enough to justify an approval.

Support, Skepticism, and Statistics: The Aducanumab Saga 

AXS-05 significantly relieved agitation, demonstrating a change from baseline in the CMAI total score of 15.4 compared to 11.5 for the placebo.

AXS-05 Shows Promise Reducing Agitation in Alzheimer Disease

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

Alzheimer Pathologic Changes Linked to Dementia With Lewy Bodies Phenotype

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Alzheimer disease research, treatment, and drug development.